• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Activated platelet-derived exosomal LRG1 promotes multiple myeloma cell growth

by | Jun 14, 2024 | Publications

Oncogenesis. 2024 Jun 13;13(1):21. doi: 10.1038/s41389-024-00522-5. ABSTRACT The hypercoagulable state is a hallmark for patients with multiple myeloma (MM) and is associated with disease progression. Activated platelets secrete exosomes and promote solid tumor...

Quality of life gains in frail and intermediate-fit patients with multiple Myeloma: Findings from the prospective HOVON123 clinical trial

by | Jun 14, 2024 | Publications

Eur J Cancer. 2024 Jun 6;207:114153. doi: 10.1016/j.ejca.2024.114153. Online ahead of print. ABSTRACT BACKGROUND: Frailty in newly-diagnosed multiple myeloma (NDMM) patients is associated with treatment-related toxicity, which negatively affects health-related quality...

Timing of Toxicities and Non-relapse Mortality Following CAR T Therapy in Myeloma

by | Jun 14, 2024 | Publications

Transplant Cell Ther. 2024 Jun 11:S2666-6367(24)00469-X. doi: 10.1016/j.jtct.2024.06.012. Online ahead of print. ABSTRACT BACKGROUND: BCMA-directed chimeric antigen receptor T-cell (CAR T) therapies, including idecabtagene vicleucel (ide-cel) and ciltacabtagene...

A five-year follow-up clinical study of the B cell maturation antigen chimeric antigen receptor-T cell therapy HDS269B in patients with relapsed or refractory multiple myeloma

by | Jun 13, 2024 | Publications

Clin Cancer Res. 2024 Jun 13. doi: 10.1158/1078-0432.CCR-24-0414. Online ahead of print. ABSTRACT PURPOSE: This study aimed to report the five-year clinical outcomes of anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) therapy in...

Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials

by | Jun 13, 2024 | Publications

J Comp Eff Res. 2024 Jun 13:e230164. doi: 10.57264/cer-2023-0164. Online ahead of print. ABSTRACT Background: Eligibility criteria are pivotal in achieving clinical trial success, enabling targeted patient enrollment while ensuring the trial safety. However, overly...

Snapper-Schneid bodies (coarse cytoplasmic granules) in a patient with multiply relapsed multiple myeloma

by | Jun 13, 2024 | Publications

Blood. 2024 Jun 13;143(24):2559. doi: 10.1182/blood.2024024221. NO ABSTRACT PMID:38869920 | DOI:10.1182/blood.2024024221
« Older Entries
Next Entries »

Recent Content

  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • (no title)
  • Correction: Activity of CAR-T cells and bispecific antibodies in multiple myeloma with extramedullary involvement
  • Sex-specific dysregulation of exosomal non-coding RNAs drives multiple myeloma progression
  • (no title)
  • (no title)
  • Multi-cohort high-dimensional proteomics reveals early risk markers for lymphoid cancer subtypes
  • 35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience
  • Hypoalbuminemia: a new risk factor for progression in patients with monoclonal gammopathy of uncertain significance
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT